CoChat

A Pilot Evaluation of the Safety and Tolerability of Repeat Dose Administration of Long‐Acting Injectable Naltrexone (Vivitrex®) in Patients With Alcohol Dependence

Johnson, Bankole A., Ait‐Daoud, Nassima, Aubin, Henri‐Jean, van den Brink, Wim, Guzzetta, Richard, Loewy, John, Silverman, Bernard, Ehrich, Elliot · 2004 · Alcoholism: Clinical and Experimental Research
Cited by 82

The DOI matches its Crossref record; 5 of the 5 references it cites were found in a registry or an index.

Abstract

Background: Oral naltrexone is currently used as part of a treatment regimen for alcohol‐dependent patients, but its clinical utility is hampered by poor patient adherence. A long‐acting injectable naltrexone formulation (Vivitrex®) was designed to facilitate patient adherence by providing an extended duration of therapeutic naltrexone over 1 month, thereby eliminating the need for daily dosing. Methods: A multicenter, randomized, double‐blind, placebo‐controlled pilot study was conducted to evaluate the safety and tolerability of intramuscular repeat dose administration of this extended‐release naltrexone formulation in DSM‐IV alcohol‐dependent patients. Thirty patients were randomized to treatment with injectable naltrexone (400 mg; n= 25) or a matching placebo injection (n= 5) and were dosed once every 28 days over 4 months. Psychosocial treatment was offered to patients in both treatment groups. Outcome measures related to drinking activity and trough plasma concentrations of naltrexone and its primary metabolite, 6‐β‐naltrexol, were evaluated. Results: Injectable naltrexone was generally safe and well tolerated. Reported adverse events were mild to moderate and resolved without intervention; only two patients discontinued due to adverse events. The most common adverse events (nausea and headache) occurred at a similar rate for patients in both treatment groups. Pharmacokinetic analysis confirmed that therapeutic levels of naltrexone were delivered throughout the four 1‐month treatment cycles. Conclusions: The results of this pilot study provide the basis and methods for a larger, more definitive trial to determine the utility of this long‐acting injectable naltrexone formulation in the treatment of alcohol‐dependent patients.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1097/01.alc.0000139823.30096.52

Cites

5 of 5 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 5 references

Cited by

See all 82

Metadata

Authors
Johnson, B. A., Ait‐Daoud, N., Aubin, H., van den Brink, W., Guzzetta, R., Loewy, J., Silverman, B., & Ehrich, E.
Venue
Alcoholism: Clinical and Experimental Research
Publisher
Wiley
Published
2004-09
Volume
28
Issue
9
Pages
1356-1361
ISSN
  • 0145-6008 (ISSN-L)
  • 1530-0277
OpenAlex
W2147784083
Cited by
82
References
5
FWCI
5.85
Type
journal article
Language
en
Open access
closed

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: A Pilot Evaluation of the Safety and Tolerability of Repeat Dose Administration of Long‐Acting Injectable Naltrexone (Vivitrex®) in Patients With Alcohol Dependence. https://app.cochat.ai/papers/10.1097/01.alc.0000139823.30096.52
The paper
Johnson, B. A., Ait‐Daoud, N., Aubin, H., van den Brink, W., Guzzetta, R., Loewy, J., Silverman, B., & Ehrich, E. (2004). A Pilot Evaluation of the Safety and Tolerability of Repeat Dose Administration of Long‐Acting Injectable Naltrexone (Vivitrex®) in Patients With Alcohol Dependence. Alcoholism: Clinical and Experimental Research. https://doi.org/10.1097/01.alc.0000139823.30096.52

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.